Drug Trial Radar · NCT04195750
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
755
Actual
Start
Feb 27, 2020
Primary completion
Apr 15, 2024
Study completion Oct 14, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.
Conditions
- Carcinoma, Renal Cell
Interventions
BelzutifanDrug
Oral tablets
EverolimusDrug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 39 months
- Overall Survival (OS)Time frame: Up to approximately 49 months
Locations
172 sites in 23 countries. Site status is shown where the registry gives one.
Faculty Office Towers 1132 ( Site 1538)
Birmingham, Alabama
University of California San Diego Moores Cancer Center ( Site 1546)
La Jolla, California
St. Joseph Heritage Healthcare Local Lab ( Site 1531)
Santa Rosa, California
University of Colorado Cancer Center ( Site 1540)
Aurora, Colorado
UCHealth Highlands Ranch Hospital ( Site 1560)
Highlands Ranch, Colorado
Sibley Memorial Hospital ( Site 1559)
Washington D.C., District of Columbia
Northwest Georgia Oncology Centers PC ( Site 1520)
Marietta, Georgia
The University of Chicago Medical Center ( Site 1539)
Chicago, Illinois
Ochsner Medical Center ( Site 1522)
New Orleans, Louisiana
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1514)
Baltimore, Maryland
Massachusetts General Hospital ( Site 1558)
Boston, Massachusetts
Beth Israel Deaconess Medical Center ( Site 1501)
Boston, Massachusetts
Dana Farber Cancer Institute ( Site 1505)
Boston, Massachusetts
Henry Ford Cancer Center ( Site 1511)
Detroit, Michigan
Hattiesburg Clinic ( Site 1509)
Hattiesburg, Mississippi
St. Vincent Frontier Cancer Center ( Site 1549)
Billings, Montana
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1513)
Hackensack, New Jersey
University of Rochester Medical Center ( Site 1543)
Rochester, New York
University of North Carolina at Chapel Hill ( Site 1537)
Chapel Hill, North Carolina
Oncology Hematology Care, Inc. ( Site 1524)
Cincinnati, Ohio
Cleveland Clinic Main ( Site 1504)
Cleveland, Ohio
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1523)
Tulsa, Oklahoma
Oregon Health & Science University ( Site 1553)
Portland, Oregon
Abramson Cancer Center ( Site 1525)
Philadelphia, Pennsylvania
Fox Chase Cancer Center ( Site 1506)
Philadelphia, Pennsylvania
Medical University of South Carolina ( Site 1518)
Charleston, South Carolina
Henry Joyce Cancer Clinic ( Site 1544)
Nashville, Tennessee
Texas Oncology-Austin Central ( Site 1533)
Austin, Texas
Texas Oncology, P.A.-Dallas ( Site 1534)
Dallas, Texas
Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 1657)
Belo Horizonte, Minas Gerais, Brazil
Instituto de Cancer e Transplante de Curitiba ICTR ( Site 1650)
Curitiba, Paraná, Brazil
Liga Norte Riograndense Contra o Cancer ( Site 1651)
Natal, Rio Grande do Norte, Brazil
Hospital de Clinicas de Porto Alegre ( Site 1655)
Porto Alegre, Rio Grande do Sul, Brazil
BP - A Beneficencia Portuguesa de São Paulo ( Site 1653)
São Paulo, São Paulo, Brazil
BC Cancer - Vancouver Center ( Site 0155)
Vancouver, British Columbia, Canada
Nova Scotia Health Authority QEII-HSC ( Site 0150)
Halifax, Nova Scotia, Canada
Juravinski Cancer Centre ( Site 0154)
Hamilton, Ontario, Canada
Sunnybrook Research Institute ( Site 0153)
Toronto, Ontario, Canada
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0151)
Montreal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0152)
Québec, Quebec, Canada
Showing 40 of 172 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.